Alcon Inc. Ordinary Shares
ALC · NYSE
Next quarter
Expected to report Nov 10, 2026 — estimated from last year’s reporting date.
Consensus is $0.89 EPS for Sep 2026 across 3 estimates, ranging $0.88 to $0.90.
ALC Jun 2026
- 9.09%
- +2.34%
- $0.77
- $0.84
- —
- —
Highlights
- Earnings beat Adjusted reported EPS was $0.84 versus consensus of $0.77, a 9.09% surprise, although IFRS diluted EPS was $0.00 after a large PowerVision-related charge.
- Revenue growth Net sales rose 8% year over year to $2.782 billion, versus $2.577 billion in the prior-year quarter and approximately $2.685 billion in the first quarter of 2026.
- PowerVision impairment Alcon recorded a $505 million non-cash impairment charge after discontinuing its PowerVision IOL programs, partly offset by a $103 million reduction in contingent consideration and a $115 million deferred-tax reversal.
- Underlying segment performance Surgical segment contribution increased 4% to $392 million, while Vision Care contribution rose 36% to $283 million; Vision Care margin expanded 4.8 percentage points to 23.3%.
- Operating profit distortion Operating income fell 96% to $11 million from $247 million, reducing operating margin to 0.4% from 9.6%; first-half operating income declined 58% to $303 million.
- Vision Care momentum Vision Care sales increased 8% to $1.212 billion, led by ocular health growth of 13% to $486 million and contact-lens growth of 5% to $726 million.
- Surgical mix Surgical sales grew 8% to $1.570 billion, led by equipment and other sales up 26% to $279 million, while implantables increased only 2% to $466 million amid continued cataract-market softness.
- Cash and capital returns First-half operating cash flow rose to $928 million from $889 million; Alcon repurchased 5.3 million shares for $364 million and authorized a further $1.5 billion buyback over three years.
Analysis
Alcon's second quarter was a revenue and adjusted-EPS beat obscured by a major strategic write-off. Net sales of $2.782 billion increased 8% year over year and were ahead of the prior quarter's approximately $2.685 billion, while reported EPS of $0.84 exceeded the $0.77 consensus estimate by 9.09%. On the statutory IFRS measure, however, diluted EPS was $0.00, compared with $0.35 a year earlier and approximately $0.39 in the first quarter, as the PowerVision discontinuation produced a post-tax non-cash charge of roughly $287 million.
The operating businesses remained healthy beneath the charge. Surgical sales rose 8% and Vision Care sales rose 8%, with particularly strong growth in equipment, ocular health and Vision Care segment profitability. Combined segment contribution increased to $675 million from $586 million, but unallocated costs rose to $664 million from $339 million, including the $505 million impairment and $33 million of second-quarter efficiency costs. Operating income consequently fell to $11 million from $247 million, despite gross margin improving to 60.2% from 53.9%. First-half operating cash flow increased to $928 million, supporting dividends, $364 million of share repurchases and the newly authorized $1.5 billion capital-return program.
PowerVision discontinuation
The quarter's headline accounting event was Alcon's decision to discontinue the PowerVision IOL programs after reviewing the latest clinical data. The decision resulted in a full $505 million impairment of the related intangible asset, recognized in research and development, and a $103 million fair-value reduction in contingent consideration liabilities. A $115 million reversal of deferred tax liabilities partly offset the charge. Alcon said the combined effect was a post-tax, non-cash net charge of approximately $287 million, which drove second-quarter net income to approximately zero and statutory diluted EPS to $0.00.
- Efficiency program Second-quarter costs associated with the February 2026 efficiency measures were $33 million; first-half costs were $121 million against an expected total implementation cost of approximately $150 million.
- Balance-sheet effect Intangible assets other than goodwill fell $736 million from year-end to $8.270 billion, primarily because of the PowerVision impairment and recurring amortization.
Segment sales momentum
Sales growth was broad, with both operating segments expanding 8% year over year. Surgical growth was supported by procedural demand, pricing and new equipment launches, while management continued to cite softness in the cataract market. Vision Care benefited from product innovation, pricing and its dry-eye portfolio, although legacy contact-lens products declined.
- Surgical Sales were $1.570 billion, up 8%; consumables rose 6% to $825 million, equipment and other increased 26% to $279 million, and implantables grew 2% to $466 million.
- Vision Care Sales were $1.212 billion, up 8%; ocular health increased 13% to $486 million and contact lenses rose 5% to $726 million.
- Product drivers PanOptix Pro supported IOL growth, Unity helped equipment sales, and Tryptyr and Systane led ocular-health growth.
Underlying profitability
The segment results were materially better than the reported operating line suggests. Surgical segment contribution increased 4% to $392 million, although its margin declined 1.0 percentage point because of product mix, tariffs and launch-related selling and marketing. Vision Care contribution rose 36% to $283 million, with margin expanding 4.8 percentage points on manufacturing efficiencies, pricing, product mix, lower tariff impact and $15 million of license revenue. The offset was a $664 million unallocated operating loss, versus $339 million a year earlier.
- Gross margin Gross profit rose 21% to $1.675 billion and gross margin expanded to 60.2% from 53.9%, helped by lower inventory-related costs and manufacturing efficiencies.
- Expense pressure Selling, general and administrative expense increased 11% to $964 million, while research and development expense rose 171% to $663 million, principally reflecting the PowerVision impairment and higher investment.
- First half First-half sales grew 9% to $5.467 billion, but operating income declined 58% to $303 million and operating margin fell to 5.5% from 14.2%.
Cash and capital allocation
Cash generation held up despite the lower reported earnings. Operating cash flow for the first half was $928 million, up from $889 million, as higher collections and lower incentive payments outweighed increased launch, tariff, research and development and efficiency spending. Investing cash use declined to $440 million from $732 million because the prior-year period included the Aurion and Cylite acquisitions.
- Share repurchases Alcon repurchased 5.3 million shares for $364 million in the first half, including 4.4 million shares for $295 million under the new program.
- New authorization The board authorized up to $1.5 billion of additional share repurchases over three years, with shares intended to be cancelled as a return of capital.
- Liquidity Cash and cash equivalents were $1.355 billion at June 30, down $172 million from year-end; the $1.32 billion revolving credit facility remained undrawn.
Tariff exposure
Tariffs remained a direct cost and an uncertainty for the outlook. Alcon incurred $39 million of tariffs in the United States and China during the first half, recognized in cost of net sales, including amounts under IEEPA and the temporary Section 122 regime. It had paid approximately $64 million of IEEPA tariffs through June 30 and had submitted a refund claim, but had not recorded a potential refund because timing and realization remained uncertain. By August 10, customs authorities had begun transmitting certain refunds.
- Surgical impact Incremental tariffs were one factor behind the 1.0 percentage-point decline in Surgical segment margin.
- Currency Favorable currency contributed approximately 1% to second-quarter sales growth in both Surgical and Vision Care.
